Firazyr

FDA approves treatment for hereditary angioedema

The U.S. Food and Drug Administration (FDA) has approved Firazyr (icatibant) Injection for the treatment of acute attacks of hereditary angioedema in people ages 18 years and older.…

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

Survey

Poll

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • This field is hidden when viewing the form

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.